Currax Pharmaceuticals v. Aurolife Pharma: 14-Patent Doxepin Sleep Drug Dispute Settled
Currax Pharmaceuticals filed suit against Aurolife Pharma in New Jersey District Court asserting 14 patents covering low-dose doxepin formulations, pharmacokinetics, and sleep-improvement methods. The action ran for 473 days before the parties reported a settlement in April 2023, administratively terminating the case.
14 Doxepin Patents, One Generic Challenger, One Settlement
Currax Pharmaceuticals, LLC filed this patent infringement action on December 30, 2021, in the District of New Jersey against Aurolife Pharma, LLC. The complaint asserted 14 US patents spanning low-dose doxepin formulations, methods of improving doxepin pharmacokinetics, and methods of using low-dose doxepin for sleep improvement — a patent portfolio consistent with protection of a branded pharmaceutical product in the sleep-disorder space. The case was assigned to Judge Christine P. O.
The recorded Basis of Termination is 'Case Settled.' The April 17, 2023 docket order states that the action has been reported as settled and administratively terminates it, explicitly noting this does not constitute a dismissal order under the Federal Rules of Civil Procedure. The order directed the parties to file dismissal papers or request reopening within 60 days, failing which the court indicated it would dismiss the action with prejudice and without costs. The specific commercial terms of the settlement are not disclosed in the available public record.
The case resolved in approximately 15.5 months — before any publicly recorded trial — which is consistent with pharmaceutical patent settlements that can involve licensing, authorised generic arrangements, or market-entry dates. What drove the parties to settle at this stage, and the substance of any agreement, remains entirely outside the public record. The breadth of the 14-patent assertion may have raised the cost and complexity of litigation for both sides, potentially accelerating resolution.
See Complete Case & Patent Analysis →Filing to Case Settled in 473 days
473 days from filing to administrative termination — typical for a multi-patent ANDA-style pharmaceutical dispute resolved before trial
US9486437B2 and 13 Further Patents — Low-Dose Doxepin Sleep Formulations
Any company developing, manufacturing, or seeking regulatory approval for a low-dose doxepin product — or a competing sleep-maintenance formulation with similar pharmacokinetic characteristics — should conduct a freedom-to-operate analysis against all 14 patents asserted in this action. The combination of formulation, method-of-use, and PK-optimisation claims creates overlapping layers of potential infringement exposure that cannot be resolved by analysing formulation patents alone.
Official order — verbatim text
The April 17, 2023 order reflects an administrative termination following a reported settlement, not a merits adjudication. The court explicitly noted the order does not constitute a dismissal under the Federal Rules, directing the parties to file formal dismissal papers within 60 days. No finding on infringement or patent validity was recorded. The public record discloses no terms of the settlement agreement.
Case settled: what the agreed resolution means for both parties
Administrative termination following reported settlement
The April 17, 2023 order administratively terminates the action after the parties reported settlement, but expressly states it is not a dismissal order under the Federal Rules of Civil Procedure. The parties were given 60 days to file formal dismissal papers. If none were filed, the court indicated it would dismiss with prejudice and without costs. The order preserves court oversight pending that formal step.
Settlement — admin terminationCurrax's 14-patent portfolio survives without adverse judgment
A settlement at this stage means none of the 14 asserted doxepin patents were adjudicated invalid or found not infringed by a court. Currax retains its patents in their current form. Whether the settlement includes any licence, consent, or market-entry provision is not disclosed in the public record — the specific terms are unknown.
No invalidity rulingAurolife avoids courtroom invalidity finding but terms undisclosed
Aurolife Pharma exits the litigation without a judicial finding on infringement or invalidity. Whether the settlement permits any path to market for a generic doxepin product — and on what timeline — is not recorded in the available public docket. The generic challenger's commercial position post-settlement cannot be assessed from public information alone.
Terms not in public recordDense patent coverage signals sustained brand protection in doxepin sleep market
Asserting 14 patents across formulation, pharmacokinetics, and method-of-use claims creates a layered exclusivity structure that any generic entrant must navigate in its entirety. Settlement — rather than a decisive patent ruling — leaves the portfolio intact and its enforceability untested in court, which may deter future generic challengers from mounting individual patent challenges piecemeal.
Layered pharma patent protectionFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Currax Pharmaceuticals, LLC | Company | /Search in Eureka ↗ |
| Defendant | Aurolife Pharma, LLC | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Jessica K. Formichella | Attorney | Counsel for Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Katelyn O. | Attorney | Counsel for Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O'Reilly Falanga LLP | Law Firm | Representing Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | R. Touhey Myer | Attorney | Counsel for Aurolife Pharma, LLCSearch in Eureka ↗ |
| Defendant law firm | Kratz & Barry, LLP | Law Firm | Representing Aurolife Pharma, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Christine P. O | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the low-dose doxepin and sleep-drug patent space
Forward-looking patent and innovation intelligence on Currax's doxepin portfolio, the sleep-disorder formulation landscape, and competitive filing activity by generic pharmaceutical companies.
Currax's doxepin IP estate spans over a decade of lifecycle filings
The 14 asserted patents include application numbers filed from 2007 through 2020, suggesting active continuation and divisional filing activity around a core doxepin programme. Tracking Currax's ongoing prosecution activity — particularly any pending continuation applications — can signal where the portfolio may expand next and what claim scope future enforcement actions might assert.
Lifecycle IP strategySleep-maintenance drug formulation patents: a growing competitive landscape
Low-dose formulations targeting sleep maintenance — rather than sleep onset — represent a distinct and growing patent cluster. Monitoring filing trends around sub-milligram dosing, modified-release oral formulations, and insomnia pharmacokinetics can identify where competitors are attempting to design around existing exclusivity or build their own IP positions in adjacent sleep-disorder indications.
Sleep pharma filing trendsAurolife Pharma's IP position in generic sleep formulations
As a generic pharmaceutical manufacturer, Aurolife's patent filings — if any — in the sleep-formulation space can indicate whether the company is building proprietary manufacturing processes or formulation know-how. Understanding a generic challenger's own IP posture helps branded companies anticipate design-around strategies and future ANDA submissions targeting the same active ingredient.
Generic challenger IPAdjacent sleep-disorder indications not covered by the doxepin patent cluster
The asserted patents focus on low-dose doxepin for sleep maintenance. Adjacent white-space opportunities may exist in combination therapies, novel delivery routes (e.g. transdermal, sublingual), or sleep-disorder indications beyond maintenance insomnia — areas where the Currax portfolio's claim scope may not extend and where new IP positions could be established.
Sleep drug white spaceSimilar pharmaceutical patent infringement cases in New Jersey District Court
Cases involving multi-patent pharmaceutical formulation and method-of-use disputes in the District of New Jersey, including low-dose drug lifecycle management actions.
What this case signals for the low-dose doxepin IP landscape
A 14-patent assertion resolved by settlement sends clear signals about pharmaceutical portfolio strategy and the risks facing generic challengers in the sleep-drug space.
Dense patent stacking is a credible litigation strategy in branded sleep pharma
Currax's assertion of 14 patents covering formulation, PK methods, and sleep-use methods illustrates how branded pharmaceutical companies can construct layered exclusivity. Each individual patent may be challenged, but the aggregate litigation burden — 14 validity and infringement analyses — significantly raises the cost of a generic challenge and may itself drive settlement.
Settlement without adverse ruling preserves the full portfolio for future enforcement
Because no court ruled on validity or infringement, all 14 Currax patents remain presumptively valid and available for future enforcement against the same or other generic filers. IP teams monitoring this space should not treat the settlement as a resolution of the underlying patent strength — it is expressly not a judicial finding either way.
Currax v Aurolife — key questions answered
Currax Pharmaceuticals asserted 14 US patents in this action: US9486437B2, US9907780B2, US10653662B2, US9861607B2, US8513299B2, US10548871B2, US9532971B2, US7915307B2, US11110074B2, US9572814B2, US9107898B2, US11096920B2, US10238620B2, and US10653660B2 — covering low-dose doxepin formulations, pharmacokinetic improvement methods, and sleep-use methods.
The recorded Basis of Termination is 'Case Settled.' The April 17, 2023 court order administratively terminated the action after the parties reported a settlement, directing them to file formal dismissal papers within 60 days. The order expressly stated it did not constitute a dismissal under the Federal Rules. The specific settlement terms are not disclosed in the public record.
No. The case settled before any judicial ruling on infringement or patent validity. All 14 asserted patents remain presumptively valid. No court finding on the merits was recorded in the available public docket.
The products at issue were low-dose doxepin formulations and the methods of making and using them, methods of improving the pharmacokinetics of doxepin, and methods of using low-dose doxepin for the improvement of sleep — consistent with a branded or generic pharmaceutical product in the sleep-maintenance indication.
The April 17, 2023 order administratively terminated the action following a reported settlement but expressly stated it was not a dismissal order under the Federal Rules of Civil Procedure. The parties were directed to file formal dismissal papers within 60 days. The court indicated that absent such filing, it would dismiss the action with prejudice and without costs. The order preserved judicial oversight pending formal resolution.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.